Zydus enters into licencing agreement with XOMA Corporation

On Monday, Zydus Cadila announced that it has entered into a licencing agreement with XOMA Corporation to advance an IL-2 based Immuno-Oncology (IO) drug candidate which combines Zydus' IL-2 with XOMA's novel anti-IL-2 monoclonal antibody. As part of the said agreement, each firm has the potential to receive pre-defined shares of future proceeds that may arise from the licencing and commercialisation activities.

Zydus Cadila will advance the new IO candidate through formal clinical trials having been granted exclusive rights to develop and commercialise the therapy in India, Brazil, Mexico and other emerging markets. On the other hand, XOMA has the potential to receive single to double-digit royalties from the commercial sales in these regions. 

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies including small molecule drugs, biologic therapeutics and vaccines.

On Monday, the stock of the company closed at Rs 258, down by 3.08 per cent or Rs 8.20 per share. The 52-week high is Rs 352.30 and the 52-week low is Rs 206.45 on BSE.